


Accepted Manuscript

The extract, the molecular allergen or both for the in vitro diagnosis of peach and peanut sensitization?

Ignazio Brusca, Maria Barrale, Rosa Onida, Stella Maria La Chiusa, Mark Gjomarkaj, Carina Gabriela Uasuf



PII: S0009-8981(19)30032-4
DOI: <https://doi.org/10.1016/j.cca.2019.01.016>
Reference: CCA 15542

To appear in: *Clinica Chimica Acta*

Received date: 17 June 2018
Revised date: 20 January 2019
Accepted date: 20 January 2019

Please cite this article as: I. Brusca, M. Barrale, R. Onida, et al., The extract, the molecular allergen or both for the in vitro diagnosis of peach and peanut sensitization?, *Clinica Chimica Acta*, <https://doi.org/10.1016/j.cca.2019.01.016>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The extract, the molecular allergen or both for the *In Vitro* diagnosis of peach and peanut sensitization?

Ignazio Brusca¹, Maria Barrale¹, Rosa Onida¹, Stella Maria La Chiusa¹, Mark Gjomarkaj²,
Carina Gabriela Uasuf².

¹*Laboratory of Clinical Pathology, "Buccheri La Ferla" Hospital, Palermo, Italy.*

²*Allergy Diseases Center "Prof. G. Bonsignore," Institute of Biomedicine and Molecular Immunology "A. Monroy" (IBIM)-National Research Council (CNR), Palermo, Italy.*

Abstract

Introduction

Identifying the target molecule in food allergies, helps to assess the risk of anaphylaxis in a patient. Lipid Transfer Protein is the most frequent cause of food allergies in the Mediterranean area. The diagnosis based on allergenic extracts, suffers from a high variability in the results because some important allergenic molecules are lacking. This study assess whether Pru p 3 and Ara h 9 molecules are significantly and sufficiently present in whole fruit allergenic extracts.

Methods

943 patients with a clinical history of suspected peach and/or peanut food allergies were recruited and underwent measurement of a specific serum IgE (ImmunoCAP system (Thermofisher/Phadia Diagnostics, Uppsala, Sweden) to the following allergens and molecules: peach (f95) and/or peanut (f13), Pru p 3 (f420), Pru p 1 (f419), Pru p 4 (f421), Ara h 1 (f422), Ara h 2 (f423) Ara h 3 (f424) and Ara h 9 (f427).

Results

Out of the 943 patients included in this study, 122 were positive to sIgE to peanut extract. At a cut-off point of 0.35 kIU/L, 62 patients were positive to sIgE to Ara h 9 but negative to peanut extract. Increasing the cut-off point of Ara h 9 at 10 kIU/L, 15 patients tested positive only to sIgE to Ara h 9. 244 out of the 943 patients were positive to sIgE to peach extract. At a cut-off point of 0.35 kIU/L, 27 patients were negative to sIgE to Pru p 3 and positive to sIgE to peach extract, whilst 11 patients were peach extract sIgE positive and sIgE negative to Pru p 1, Pru p 3 and Pru p 4. Only 12 patients tested positive to Pru p1 and/or Pru p 4.

Conclusion

Our data strongly suggests to include the measurement of sIgE to Ara h9 into the diagnostic algorithm of peanut sensitization. 4.5% of the Sicilian population suspected of Peach sensitization were positive to Peach whole extract and negative to all the molecules available.

ACCEPTED MANUSCRIPT

1.1 Introduction

In recent years, component resolved diagnosis (CRD) has greatly improved diagnostic precision in the fields of respiratory and IgE-mediated food allergy [1]. The ability to identify the target molecule involved in the allergic sensitization has opened up new horizons from which to approach allergic diseases. Particularly in the field of food allergy, CRD helps to improve the risk assessment of allergic patients by distinguishing between the sensitization of extremely cross-reactive labile molecules (PR-10, Profilin) and highly stable allergenic molecules with an elevated number of possible molecules cross-reacting (Lipid Transfer Protein, serum Albumin, and Parvalbumin) or molecules which are particularly stable but with a limited number of cross-reactions (Seed Storage Protein, Casein and Ovomucoid) [2]. Using this method, it has been possible to identify different geographical European molecular patterns of sensitization, leading to the presence of a north-south gradient. At higher European latitudes, sensitization to Profilin and PR-10 molecules prevails, while sensitization to LTP [3-11] is more frequent in the south.

A study conducted in Sicily has confirmed that sensitization to LTP is the most common cause of food allergy in the area and it has been frequently found as an isolated sensitization rather than being associated with other panallergenic molecules [11].

Diagnosis based on allergenic extracts, particularly when it uses the skin prick test, suffers from a high variability in the results, not only qualitative but also quantitative, between different producers of the same allergenic product and between different batches of the same allergen [12-23]. In addition to the lack of standardization, it has been shown that some important allergenic molecules (including Hev b 5, Gly m 4, Omega-5 gliadin) are lost during the extraction process. Thus, if the producer does not intervene artificially by adding the molecule to the extract, it will be present in a very low concentration level [24-30]. For example, Prolamins, such as omega-5-gliadin, which is responsible for severe allergic reactions, are not always well represented in the allergenic extracts due to their chemical characteristics [29-30].

In this study we assessed whether the diagnostic sensitivity of allergenic extracts to Peanut and Peach, in a population mainly sensitized to LTP molecules, is adequate. The study's intent was not to evaluate the clinical features of the allergic sensitization to peach and peanut allergens.

2.1 Materials and methods

Between October 2015 and March 2016, we recruited 943 outpatients with a suspected food allergy and an anamnesis suggestive of possible sensitization to Peach or Peanut, consecutively referring to the Allergy Diseases Center, IBIM – CNR and the Allergy Unit, Buccheri La Ferla Hospital, Palermo, Sicily. The mean age was 37.8 (S.D.: ± 27.4 , range 3-62 years), n. 627 (66.5%) females, n.316 (33.5%) males, 67 of them aged <7 years. All individuals reporting clinical manifestations potentially due to allergic reactions (asthma, rhinitis, conjunctivitis, urticaria/angioedema, abdominal pain, diarrhea, vomiting or anaphylaxis) after eating meals including one of these fruits underwent the Skin Prick Test (SPT) with extract of Peach and Peanut, (ALK Abello, Spain). Furthermore, on the basis of clinical history suggestive of possible sensitization to Peach or Peanut, the recruited outpatients were tested for the specific serum IgE (ImmunoCAP system (Thermofisher/Phadia Diagnostics, Uppsala, Sweden). Specifically, six hundred and thirty-one outpatients having a suspected allergic reaction after a meal including peach were tested for Specific IgE (sIgE) with Peach (F95), Pru p 3 (F420), Pru p 1 (F419), Pru p 4 (F421). Furthermore, 312 outpatients having a suspected allergic reaction after a meal including peanut were tested with extract of Peanut (F13), Ara h 1 (F422), Ara h 2 (F423) Ara h 3 (F424), Ara h 9 (F427), Pru p 1 (F419), Pru p 4 (F421). As a result, 569 outpatients that resulted negative to both of the previous tests were excluded from the study. After a further depth clinical revaluation, in 32 outpatients positive to Peanut and in 84 outpatients positive to Peach the role of these allergens, to elicit the allergic reaction, was not confirmed. These subjects, in fact, ate Peanut or Peach again without reaction and then they underwent another diagnosis. 98 outpatients positive to Peanut and 162

outpatients positive to Peach presented a very convincing history of allergic reaction to these foods and were stratified as confirmed.

Results were expressed in kIU/L and values >0.35 kIU/L were considered positive. Figure 1 represents the flowchart of the outpatients' positivity both for Peanut sensitization and Peach sensitization

2.2 Data analysis

Statistical analysis was performed with MedCalc software, version 18.2.1. Mean values with standard deviations were calculated. McNemar's test was applied to explore any statistical difference in positive/negative results in the "in vitro" tests. The Mann-Whitney test was used to compare the allergenic whole extract of Peanut and Peach by LTP. A comparison between the same groups was made using linear regression, Passing-Bablok regression and the concordance coefficient. Results were considered significant when p-value was < 0.05 .

3.0 Results

Table 1 summarizes the positivity of outpatients with SPT, sIgE for F13, Ara h 9, F95 and Pru p 3. Fifty-six outpatients out of the 312 included in the Peanut group were positive to SPT with the Peanut whole extracts. If using a sIgE cut-off point of 0.35 kIU/L, the subjects positive to F13 extract numbered 60. Interestingly, with the same sIgE cut-off, 122 outpatients were positive to Ara h 9. The distribution of specific IgE levels for F13 whole extracts and Ara h 9 is represented in Figure 2 using the Box-and-Whisker plot. The Mann-Whitney test underlined a significant difference between the F13 and Ara h 9 results (median values 0.0200 and 0.0500 kIU/L, respectively; p-value= 0.0009). The results of the Passing-Block regression between Ara h 9 and peanut is shown in Figure 3. The arithmetic average and standard deviation between peanut and

Ara h 9 was 0.857 ± 3.144 and 3.571 ± 11.759 kIU/L, respectively. The regression Equation was $y = -0.288 + 30.318 x$. The concordance coefficient between peanut and Ara h 9 was of 0.0227 with a 95% Confidence interval (CI) of -0.0759 -0.1210. Of the sensitized outpatients, 98 were symptomatic after the ingestion of peanuts, 9 with local oral symptoms and 89 with systemic symptoms (eg. urticaria and/or angioedema, anaphylaxis). In these peanut confirmed outpatients, the Mann-Whitney test highlighted a statistically significant difference between F13 and Ara h 9 levels, with median values of 0.01000 and 3.4750 kIU/L, respectively (p-value < 0.0001), while in subjects not confirmed the median was of 0.0200 and 0.0050 kIU/L (p-value = 0.0002), respectively. Figure 4 represents the distribution of specific IgE levels for F13 whole extracts and Ara h 9 in confirmed and not confirmed outpatients.

For Peach sensitization, 219 outpatients were positive to SPT, 244 to sIgE F95, 217 with Pru p 3, 12 to Pru p 4 and 4 to Pru p 1. Figure 5 shows the Box-and-Whisker plot of the distribution of specific IgE levels for F95 whole extracts and Pru p 3. The Mann-Whitney test didn't highlight a statistically significant difference between F95 and Pru p 3 levels (median values 0.0400 and 0.0400 kIU/L, respectively; p-value= 0.1138). The Passing-Bablok regression between Pru p 3 and peach is shown in Figure 6. The arithmetic average and standard deviation between peach and Pru p 3 were 3.8379 ± 11.3103 and 4.3713 ± 13.3829 kIU/L, respectively, and the regression equation was $y = 0.0038 + 1.154 x$. The concordance coefficient between Pru p 3 and peach was of 0.8840 (95%CI: 0.8642-0.9985).

Interestingly, 11 of the F95-positive outpatients resulted negative to all the peach molecules available. Of the outpatients sensitized, 156 were symptomatic after the ingestion of peach, 12 with local oral symptoms and 144 with systemic symptoms (eg. urticaria and/or angioedema, anaphylaxis). The Mann-Whitney test was calculated both in these and in not confirmed peach sensitized outpatients, but there was no statistically significant difference between F95 and Pru p 3 both in confirmed outpatients (median values 0.02500 and 0.0300 kIU/L, respectively; p-value= 0.0791), while in not confirmed subjects (medians 0.0400 and 0.0400 kIU/L) the p-value was equal

to 0.0235). The Mac Nemar test confirms a statistically significant difference between F95 and Pru p 3 in peach not confirmed subjects ($p < 0.0001$); table 1). Figure 7 shows the distribution of IgE levels of F95 and Pru p 3. in confirmed and not confirmed outpatients: there was no significant difference between SPT and SIgE whole extracts for Peanut and Peach.

4.0 Discussion

Peanuts are one of the main allergenic sources responsible for serious allergic reactions throughout the world. Frequently, sensitization involves the seed storage proteins, particularly Ara h 2 [32-36]. However, in some geographical regions the most frequent sensitization is not Ara h 2 but Ara h 9 [37-39].

Lauer *et al.* compared Mediterranean with non-Mediterranean patients allergic to peanuts and found that the former had a prevalence of sensitization to Ara h 9 of 90.6% and the latter only of 14.6% [38]. Using Microarray ISAC, Goikoetxea *et al.* reported a sensitization of the peanut LTP of 66.6% [40].

Results from Sicilian patients sensitized to peanuts showed a high prevalence of sIgE to Ara h 9. Indeed, at a cut-off point of 0.35 kIU/L in the studied population the sensitization was equal to 39.1%, predominant as compared with the sensitization to Seed Storage Proteins (6.1%).

It is surprising that when using the whole extract in the diagnosis the sensitivity decreased by only 19.2 %.

Several studies have evaluated the sensitivity of specific IgE to peanut extract [41-44], focusing on the clinical output. A recent review highlighted that the sensitivity to the peanut extract was between 80% and 100% [45], but none of the studies were performed using a Mediterranean population. By contrast, studies from Japan, Thailand, Sweden, and Denmark have found a sensitivity of Ara h 9 between 8.6% and 26%. Our study pointed out that the sensitivity to F13 in confirmed outpatients, mainly sensitized with LTP, was of 42.9%, while the sensitivity of Ara h 9 was equal to 100%. A significant difference was shown between the results obtained with F13 and

Ara h 9 both in not confirmed and in confirmed patients. Our findings documented an absence of correlation and concordance between peanut whole extract and Ara h 9. Our study is not in contrast with previous studies where the populations are different and they have different molecular patterns of allergic sensitization. Due to the allergenic importance of Ara h 9, use of peanut extract in the diagnostic algorithm of peanut sensitization in the Mediterranean populations was not considered to be suitable as a screening test, but it requires measurement of the LTP molecule. The very low prevalence of sensitization to the other peanut molecules did not allow us to add statistically relevant results relative to the diagnostic sensitivity of peanut extract in outpatients sensitized to them.

In contrast, the measurements of the sIgE to peach extract and Pru p 3 showed a high degree of correlation between both tests, confirming the predominant sensitization of Pru p 3 in the Sicilian population [11,46]. Anyway, the Mann-Whitney test highlights a significant difference between F95 and Pru p 3 only in not confirmed subjects. This data supports the study done by Gamboa *et al.* [47] in a Mediterranean population. A comparison between the positivity to sIgE to peach extract and the negativity to sIgE Pru p 3 is rather interesting. Indeed, peach contains another allergen called Peamaclein (Pru p7) that is responsible for important allergic reactions, but no specific commercial test is available at the moment [49-49]. This allergen is present in the pulp, while LTP is predominantly located in the skin of the fruit [50]. The sensitization to Pru p7 could be suspected in patients who are positive to whole peach extract but negative to all other molecular peach allergens (Profilin, PR10 and Pru p 3).

A recent study conducted in a Japanese population demonstrated the high prevalence of sensitization to Pru p7 (13%) with a co-sensitization to Pru p 3 in 2% of patients. Interestingly, data from symptomatic peach allergic patients from France showed 78% of sensitization to Pru p7 (cut-off point > 0.1) and 31% of sensitization in a-symptomatic patients. Sensitization to Peamaclein is clinically associated with severe symptoms [51].

This study shows that 4.5% of patients positive to peach extract were negative to Pru p 3, Profilin, and PR10. This result was probably determined by sensitization to other molecules contained in the extract as Peamaclein or other unknown molecules. Nevertheless, only after the availability of a specific tests will it be possible to identify the target allergen.

Lastly, the findings related to Profilin and PR-10 confirm the low predominant sensitization of these molecules in patients with food allergy in Sicily as it was previously observed in a high number of patients [11, 46].

5.0 Conclusion

This study strongly highlights the importance of including measurement of sIgE Area h 9 in the diagnostic algorithm of peanut sensitization.

References

- 1] Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, et al. EAACI Molecular Allergology User's Guide. *Pediatr Allergy Immunol.* 27 (suppl23) (2016) 1–250.
- 2] Borres MP, Maruyama N, Sato S, Ebisawa M. Recent advances in component resolved diagnosis in food allergy. *Allergol Int.* 65(4) (2016) 378-87.
- 3] Ballmer-Weber BK, Scheurer S, Fritsche P, et al. Component-resolved diagnosis with recombinant allergens in patients with cherry allergy. *J Allergy Clin Immunol.* 110 (2002) 167–73.
- 4] Fernandez-Rivas M, Gonzalez-Mancebo E, Rodriguez-Perez R, et al. Clinically relevant peach allergy is related to peach lipid transfer protein, Pru p 3, in the Spanish population. *J Allergy Clin Immunol.* 112 (2003) 789–95.
- 5] Fernandez-Rivas M, Bolhaar S, Gonzalez Mancebo E, et al. Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods. *J Allergy Clin Immunol.* 118 (2006) 481–8.
- 6] Barber D, de la Torre F, Lombardero M, et al. Component-resolved diagnosis of pollen allergy based on skin testing with profilin, polcalcin and lipid transfer protein pan-allergens. *Clin Exp Allergy.* 39 (2009) 1764–73.
- 7] Asero R, Antonicelli L, Arena A, et al. Causes of food-induced anaphylaxis in Italian adults: a multi-centre study. *Int Arch Allergy Immunol.* 150 (2009) 271–7.

- 8] Pastorello EA, Farioli L, Stafylaraki C, et al. Anti-rPru p 3 IgE levels are inversely related to the age at onset of peach-induced severe symptoms reported by peach allergic adults. *Int Arch Allergy Immunol.* 150 (2013) 162: 45-9.
- 9] Gomez F, Aranda A, Campo P, et al. High prevalence of lipid transfer protein sensitization in apple allergic patients with systemic symptoms. *PLoS One.* 9 (2014) e107304.
- 10] Mothes-Luksch N, Raith M, Stingl G, et al. Pru p 3, a marker allergen for lipid transfer protein sensitization also in Central Europe. *Eur Ann Allergy Clin Immunol.* 49(1) (2017) 45-8.
- 11] Uasuf CG, Villalta D, Conte ME, et al. Different co-sensitizations could determine different risk assessment in peach allergy? Evaluation of an anaphylactic biomarker in Pru p 3 positive patients. *Clin Mol Allergy.* 2 (2015) 13:30.
- 12] Meyer CH, Bond JF, Chen MS, et al. Comparison of the levels of the major allergens Der p I and Der p II in standardized extracts of the house dust mite, *Dermatophagoides pteronyssinus*. *Clin Exp Allergy.* 24(11) (1994) 1041-8.
- 13] van der Veen MJ, Mulder M, Witterman AM, et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (*Dermatophagoides pteronyssinus*) allergens. *J Allergy Clin Immunol.* 98(6 Pt 1) (1996) 1028-34.
- 14] Focke M, Marth K, Flicker S, et al. Heterogeneity of commercial timothy grass pollen extracts. *Clin Exp Allergy.* 38(8) (2008) 1400-8.
- 15] Pagani M, Antico A, Cilia M, et al. Comparison of different diagnostic products for skin prick testing. *Eur Ann Allergy Clin Immunol.* 41(1) (2009) 23-31.
- 16] Brunetto B, Tinghino R, Braschi MC, et al. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. *Allergy.* 65(2) (2010) 184-9.
- 17] Rossi R, Monasterolo G, Passalacqua G. The biological potency of different extracts for sublingual immunotherapy assessed by skin prick tests. *Eur Ann Allergy Clin Immunol.* 42(3) (2010) 112-4.
- 18] Curin M, Reininger R, Swoboda I, et al. Skin prick test extracts for dog allergy diagnosis *Immunol.* show considerable variations regarding the content of major and minor dog allergens. *Int Allergy* 154 *Arch* (2011) 258-63.
- 19] Casset A, Mari A, Purohit A, et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial *Dermatophagoides pteronyssinus* extracts. *Int Arch Allergy Immunol.* 159 (2012) 253-62
- 20] Kespohl S, Maryska S, Zahradnik E, et al. Biochemical and immunological analysis of mould skin prick test solution: current status of standardization. *Clin Exp Allergy.* 43(11) (2013) 1286-96.
- 21] Gabriel MF, Tavares-Ratado P, Peixinho CM, et al. Evaluation and comparison of commercially available latex extracts for skin prick tests. *J Investig Allergol Clin Immunol.* 23(7) (2013) 478-86.

- 22] van Kampen V, de Blay F, Folletti I, Kobierski P, Moscato G, Olivieri M, et al. Evaluation of commercial skin prick test solutions for selected occupational allergens. *Allergy*. 68(5) (2013) :651-8.
- 23] Asero R, Scala E, Villalta D, et al. Shrimp Allergy: Analysis of Commercially Available Extracts for In Vivo Diagnosis. *J Invest Allergol Clin Immunol*. 27(3) (2017) 175-82.
- 24] Berneder M, Bublin M, Hoffmann-Sommergruber K, et al. Allergen chip diagnosis for soy-allergic patients: Gly m 4 as a marker for severe food-allergic reactions to soy. *Int Arch Allergy Immunol*. 161(3) (2013) 229-33.
- 25] Hamilton RG, Peterson EL, Ownby DR. Clinical and laboratory-based methods in the diagnosis of natural rubber latex allergy. *J Allergy Clin Immunol*. 110(2002) S4756.
- 26] Alenius H, Turjanmaa K, Palosuo T. Natural Rubber Latex Allergy. *Occup Environ Me*. 59 (2002) 419–24.
- 27] Biagini RE, MacKenzie BA, Sammons DL, et al. Latex specific IgE: performance characteristics of the IMMULITE 2000 3gAllergy assay compared with skin testing. *Ann Allergy Asthma Immunol*. 97(2) (2006) 196-202.
- 28] Tatham AS, Shewry PR. Allergens to wheat and related cereals. *Clin Exp Allergy*. 38(11) (2008) 1712-26.
- 29] Morita E, Chinuki Y, Takahashi H. Recent advances of in vitro tests for the diagnosis of food-dependent exercise-induced anaphylaxis. *J Dermatol Sci*. 71(3) (2013) 155-9.
- 30] Pacharn P, Kumjim S, Tattiyapong P, et al. Identification of wheat sensitization using an in-house wheat extract in Coca-10% alcohol solution in children with wheat anaphylaxis. *Asian Pac J Allergy Immunol*. 34(2) (2016) 153-8.
- 31] Tuppo L, Alessandri C, Pomponi D, et al. Peamaclein—a new peach allergenic protein: similarities, differences and misleading features compared to Pru p 3. *Clin Exp Allergy*. 43 (2013) 128–40.
- 32] Koppelman SJ, Wensing, Ertmann M, et al. Relevance of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by immunoglobulin E Western blotting, basophil histamine release and intracutaneous testing: Ara h2 is the most important peanut allergen. *Clin Exp Allergy*. 34 (2004) 583–90.
- 33] Flinterman AE, van Hoffen E, den Hartog Jager CF, Koppelman S, Pasmans SG, Hoekstra MO Children with peanut allergy recognize predominantly Ara h2 and Ara h6, which remains stable over time. *Clin Exp Allergy*. 37 (2007) 1221–8.
- 34] Nicolaou N, Poorafshar M, Murray C, et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. *J Allergy Clin Immunol*. 125 (2010) 191–7.
- 35] Beyer K, Grabenhenrich L, Hartl M, et al. Predictive values of component specific IgE for the outcome of peanut and hazelnut food challenges in children. *Allergy*. 70 (2015) 90–8.

- 36] Agabriel C, Ghazouani O, Birnbaum J, et al. Ara h 2 and Ara h 6 sensitization predicts peanut allergy in Mediterranean pediatric patients. *Pediatr Allergy Immunol.* 25 (2014) 662–7.
- 37] Lauer I, Dueringer N, Pokoj S, Rehm S, Zoccatelli G, Reese G et al. The non-specific lipid transfer protein, Ara h9, is an important allergen in peanut. *Clin Exp Allergy.* 39 (2009) 1427–37.
- 38] Krause S, Reese G, Randow S, et al. Lipid transfer protein (Ara h9) as a new peanut allergen relevant for a Mediterranean allergic population. *J Allergy Clin Immunol.* 124(4) (2009) 771-8.
- 39] Ma S, Nie L, Li H, Wang R, Yin J. Component-Resolved Diagnosis of Peanut Allergy and Its Possible Origins of Sensitization in China *Int Arch Allergy Immunol.* 169(4) (2016) 241-8.
- 40] Goikoetxea MJ, D'Amelio CM, Martínez-Aranguren R, et al. Is Microarray Analysis Really Useful and Sufficient to Diagnose Nut Allergy in the Mediterranean Area? *J Investig Allergol Clin Immunol.* 26 (2016) 31-9.
- 41] Nolan RC, Richmond P, Prescott SL, et al. Skin prick testing predicts peanut challenge outcome in previously allergic or sensitized children with low serum peanut-specific IgE antibody concentration. *Pediatr Allergy Immunol.* 18 (2007) 224–30.
- 42] Wainstein BK, Yee A, Jelley D, et al. Combining skin prick, immediate skin application and specific-IgE testing in the diagnosis of peanut allergy in children. *Pediatr Allergy Immunol.* 18 (2007) 231–9
- 43] Johannsen H, Nolan R, Pascoe EM, et al. Skin prick testing and peanut specific IgE can predict peanut challenge outcomes in preschool children with peanut sensitization. *Clin Exp Allergy.* 41 (2011) 994–1000.
- 44] Nicolaou N, Murray C, Belgrave D, et al. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. *J Allergy Clin Immunol.* 127 (2011) 684–5.
- 45] Klemans RJ, van Os-Medendorp H, Blankestijn M, et al. Diagnostic accuracy of specific IgE to components in diagnosing peanut allergy: a systematic review. *Clin Exp Allergy.* 45 (2015) 720-30.
- 46] Uasuf CG, Sano CD, Gangemi S, et al.. *Inflamm Res.* 67(8) (2018) 671-79 (2018) 47]
- 47] Gamboa PM, Sanz ML, Lombardero M, et al. Component-resolved in vitro diagnosis in peach-allergic patients. *J Investig Allergol Clin Immunol.* 19(1) (2009) 13-20.
- 48] Inomata N, Okazaki F, Moriyama T, Nomura Y, Yamaguchi Y, Honjoh T, et al. Identification of peamaclein as a marker allergen related to systemic reactions in peach allergy. *Ann Allergy Asthma Immunol.* 112 (2014) 175-77.
- 49] Tuppo L, Spadaccini R, Alessandri C, et al. Structure, stability, and IgE binding of the peach allergen Peamaclein (Pru p 7). *Biopolymers.* 102(5) (2014) 416-25.

- 50] Inomata N, Miyakawa M, Aihara M. High prevalence of sensitization to gibberellin-regulated protein (peamaclein) in fruit allergies with negative immunoglobulin E reactivity to Bet v 1 homologs and profilin: Clinical pattern, causative fruits and cofactor effect of gibberellin-regulated protein allergy. *J Dermatol.* 44(7) (2017) 735-41.
- 51] Klingebiel C, Poisson A, Lidholm J, et al. Pru p 7 is a major allergen and a severity marker in peach allergic patients from Southern France 1616 EAACI 17-21 June Helsinki

	slgE whole extracts	slgE LTP (Ara h9 and Pru p3)	p*	Pru p4	Prup1	Ara h1	Ara h2	Ara h3	Skin Prick test whole extracts
Peanut n.312	60/312 (19.2%)	122/312 (39.1%)	p < 0,0001	0	0	2 (0.64%)	5 (1.6%)	1 (0.32%)	56 (17.9%)
Peach n.631	244/631 (38.7%)	217/631 (34.4%)	p < 0,0001	12(1.9%)	4 (0.63%)				219 (34.7%)
Peanut confirmed n.98/312	42/98 (42.9%)	98/98 (100%)	p < 0,0001						39 (39.8%)
Peanut not confirmed 214/312	18/214 (19.2%)	24/214 (11.2%)	p<0.0001						17 (7.9%)
Peach confirmed 162/631	160/162 (98.8%)	162/162 (100%)	p=0.5						159 (98.1%)
Peach not confirmed 469	84/469 (17.9%)	55/469 (11.7%)	p<0.0001						60 (12.8%)

Table 1. Characteristics of sensitization to Peanut and Peach in 943 outpatients studied (slgE cut-off 0,35 kIU). *Mc Nemar test

- A lot of sensitized patients negative to peanut extract are positive to Ara h9
- Peanut extract is not considered to be suitable as a screening test of peanut allergy
- 4.5% of the Sicilian population suspected of Peach sensitization were positive to Peach whole extract and negative to all the molecules available.




Figure 1




Figure 2




Figure 3





Figure 4




Figure 5




Figure 6





Figure 7